Alembic Pharmaceuticals Q2 Results Live: Profit Rise by 12.33% YOY

Alembic Pharmaceuticals Q2 Results Live : Alembic Pharmaceuticals declared their Q2 results on 07 Nov, 2024, reporting a topline increase of 3.33% and a profit rise of 12.33% year-over-year. Compared to the previous quarter, the company experienced a revenue growth of 5.52% and a profit increase of 14.16%.

The financial report also highlighted that selling, general, and administrative expenses rose by 3.08% quarter-over-quarter and increased by 12.82% year-over-year. This rise in expenses has raised concerns about the company's cost management strategies.

Operating income saw a significant jump, up by 8.24% quarter-over-quarter and an impressive 29.09% year-over-year, indicating strong operational efficiency despite rising expenses. The earnings per share (EPS) for Q2 stood at ₹7.24, reflecting a 4.1% increase from the same period last year.

In terms of stock performance, Alembic Pharmaceuticals has faced a -4.34% return in the last week, although it boasts a 7.84% return over the past six months and a remarkable 42.2% year-to-date return.

As of now, Alembic Pharmaceuticals has a market capitalization of ₹21,226.85 Cr, with its stock trading between a 52-week high of ₹1303.9 and a low of ₹710.25. Analysts remain cautiously optimistic, with 1 analyst rating it a 'Sell', 6 'Hold', and 2 giving a 'Strong Buy' rating.

The consensus recommendation, as of 08 Nov, 2024, is to 'Hold', reflecting a balanced view on the company’s performance and market conditions.